Premium
Fluorodeoxyuridine causes bilomas after hepatic cryotherapy
Author(s) -
Soon Patsy S.,
Glenn Derek,
Jorgensen John,
Morris David L.
Publication year - 1998
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199809)69:1<45::aid-jso9>3.0.co;2-k
Subject(s) - cryotherapy , medicine , chemotherapy , complication , fluorouracil , surgery , toxicity
Background and Objectives: Hepatic cryotherapy is a method of in situ cytodestruction used for unresectable liver tumours that can be combined with regional cytotoxic administration. We have used intra‐arterial chemotherapy with 5‐fluorouracil (5‐FU) after hepatic cryotherapy but changed to 5‐fluorodeoxyuridine (FUDR) because of the arterial toxicity of 5‐FU. A new complication was seen. Methods A retrospective case note study was performed of 130 patients who had undergone hepatic cryotherapy followed by regional chemotherapy at our centre. Seven patients received FUDR; 123 received 5‐FU. Results Biloma at the cryotherapy sites was seen in three patients in the FUDR group; two other patients in this group had other types of hepatic collection. Our previous experience with intra‐arterial 5‐FU in 123 patients after hepatic cryotherapy showed no evidence of this syndrome. Conclusions Intra‐arterial FUDR should not be used after hepatic cryotherapy, at least during the immediate postoperative period. J. Surg. Oncol. 1998;69:45–50. © 1998 Wiley‐Liss, Inc.